GB-102, our lead product, contains a single small molecule compound that inhibits multiple pathogenic angiogenesis pathways known to be involved in the choroidal neovascularization, the cause of neovascular (wet) AMD (nAMD). Blockage of these angiogenesis pathways together has been shown to be more effective than blockage of a single pathway in clinical studies of nAMD.
Graybug Vision is developing products to reduce the frequency of dosing for ocular therapies using its injectable controlled release technologies. Our pipeline products cover major eye indications that might lead to blindness, including neovascular (wet) age-related macular degeneration (nAMD), glaucoma, and corneal graft rejection.
Graybug Vision’s proprietary drug delivery technologies have broad applicability to all classes of therapeutics, including investigational drugs currently under development, and marketed drugs. Our world-class team and advisors are experts in the development of controlled-release products and the treatment of ocular disease.